Source - SMW
Amryt Pharma has appointed Derval O'Carroll as its head of regulatory affairs.

Previously, O'Carroll was senior director of regulatory affairs for NASDAQ-listed rare diseases company Retrophin. 

She had also served as a managing consultant at Real Regulatory, a consultancy specialising in European regulatory affairs.


At 2:27pm: (LON:AMYT) Amryt Pharma share price was 0p at 20.25p



Related Charts

Amryt Pharma (AMYT)

0.00 (0.00%)
delayed 16:57PM